Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients

Table 1 Characteristics of the subjects tested¹

Groups	n	Male	Female	M/F	Median age (range), yr
Donors	40	12	28	0.43	52.2 (23–70)
Benign group2	22	19	3	6.3	62.0 (44–76)
Non-cancer3	62	31	31	1	59.5 (23–76)
Cancer patients	89	53	36	1.47	66.0 (22–84)
Stages 1-4
Stage 1	18	8	10	0.86	65.0 (28–84)
Stage 2	19	14	5	1.67	66.5 (46–83)
Stage 3	42	22	20	0.83	65.0 (38–81)
Stage 4	10	9	1	9	65.0 (44–76)

¹All subjects were tested for anti-Thomsen-Friedenreich glycotope IgG levels and the concanavalin A binding. Aleuria aurantia lectin and Sambucus nigra agglutinin binding test was performed in all donors and patients with benign gastric disease, and in 33 patients with stomach cancer (stage 1, n = 4; stage 2, n = 5; stage 3, n = 19; stage 4, n = 5);

²Peptic ulcer disease, n = 6; chronic gastritis, n = 7; atrophic gastritis, n = 9;

³Combined group of donors and patients with benign stomach disease. M/F: Male/female.

Table 2 Anti-TF IgG level and lectin binding profile: Sensitivity and specificity for gastric cancer

Parameter	Sensitivity % (95%CI)	Specificity % (95%CI)	ROC statistics		Sensitivity at specificity 90%
			Area under curve	P value
Anti-TF IgG	65.17 (51.34-76.26)	67.74 (56.66-76.98)	0.70	< 0.0001	50.56
ConA	62.92 (48.37-74.49)	56.90 (46.37-67.74)	0.64	0.004	24.72
SNA	78.79 (61.09-91.02)	79.17 (65.01-89.53)	0.87	< 0.0001	57.58
AAL	69.70 (51.29-84.41)	64.58 (49.46-77.84)	0.68	0.006	12.12
ConA/SNA	72.73 (57.21-85.04)	88.64 (71.80-96.60)	0.91	< 0.0001	63.64
AAL/ConA	84.85 (68.10-94.89)	68.18 (52.42-81.39)	0.78	< 0.0001	33.33
AAL/SNA	84.85 (72.24-93.93)	47.92 (30.80-66.46)	0.68	0.006	3.03

ConA: Concanavalin A; AAL: Aleuria aurantia lectin; SNA: Sambucus nigra agglutinin; Anti-TF IgG: Anti-Thomsen-Friedenreich glycotope immunoglobulin G; ROC: Receiver operator characteristic.